Immunization coverage and safety of the 23-valent pneumococcal polysaccharide vaccine in Guang-zhou from 2010 to 2015

Jian Chen; Jianxiong XU; Chunhuan Zhang; Huifeng Tan; Zhiqun LI

Return

Immunization coverage and safety of the 23-valent pneumococcal polysaccharide vaccine in Guang-zhou from 2010 to 2015

VernacularTitle:2010-2015年广州市23价肺炎球菌多糖疫苗接种情况及安全性分析
Author: Jian CHEN ; Jianxiong XU ; Chunhuan ZHANG ; Huifeng TAN ; Zhiqun LI
Publication Type:Journal Article
Keywords: 23-valent pneumococcal polysaccharide vaccine; Vaccination status; Adverse events following immunization; Safety
From: Chinese Journal of Microbiology and Immunology 2016;36(5):380-383
CountryChina
Language:Chinese
Abstract: Objective To analyze the immunization coverage of 23-valent pneumococcal polysac-charide vaccine(PPV23)in a large population in Guangzhou and to evaluate its safety by analyzing the ad-verse events following immunization(AEFI)reported to the passive surveillance system. Methods Immu-nization data of PPV23 in Guangzhou from 2010 to 2015 were collected from Information Management System of Biological Products and the Information System of Immune Programming of Guangzhou. AEFI reported to the AEFI Information System during 2010 to 2015 was collected for safety evaluation. The collected data were analyzed by using descriptive methodology. Results A total of 621 059 doses of PPV23 were pre-scribed in Guangzhou from 2010 to 2015. Most of the recipients were children younger than 10 years old,ac-counting for 79. 44% . Only 9. 38% of the subjects received PPV23 were older than 60 years. A total of 243 AEFI cases were reported at a rate of 39. 13 cases per 100 000 doses,among which 199 cases(32. 04 / 105 ) showed minor vaccine reactions,25 cases(4. 03 / 105 )occurred adverse events,16 cases(2. 58 / 105 )de-veloped coupled diseases and 3 cases(0. 48 / 105 )were classified as psychogenic reactions. No rare adverse reactions were observed. Conclusion The majority of people immunized with PPV23s in Guangzhou were children,while the immunization coverage among the elderly was relatively low. PPV23 was safe for vaccina-tion as the reported AEFI cases were similar to that of other vaccines.